AN ACT relating to utilization controls for nonopioid analgesics in the Medicaid program.
Summary
SB56 would restrict how Kentucky Medicaid, its managed care organizations, and the state pharmacy benefit manager may manage coverage for nonopioid prescription pain medications. If a licensed physician prescribes a nonopioid drug for acute or chronic pain, the bill prohibits denying coverage in favor of an opioid and bars the use of more restrictive prior authorization, step therapy, or other utilization controls on clinically appropriate nonopioid drugs than those applied to comparable opioid or narcotic drugs.
The bill also directs the Cabinet for Health and Family Services or the Department for Medicaid Services to seek any needed federal approval within 90 days if implementation would otherwise risk federal funding or conflict with federal law. If federal approval is required, implementation may be delayed only for the affected provisions until approval is received. The bill further states that its provisions serve as the specific authorization required under existing Kentucky Medicaid law.
Impact
SB56 would amend Kentucky Medicaid administration by creating new restrictions on coverage management for nonopioid analgesics and related pain medications. It would affect the Department for Medicaid Services, Medicaid managed care organizations, and the contracted pharmacy benefit manager by limiting their ability to prefer opioids over prescribed nonopioid options and by standardizing utilization controls so nonopioid drugs are not subjected to more burdensome review than comparable opioid or narcotic drugs. The bill also interacts with federal Medicaid requirements by requiring the state to seek any necessary waiver, state plan amendment, or other approval before implementation if needed to preserve federal funding or comply with federal law.
Sentiment
The available voting history suggests broad bipartisan support for the bill. It passed the Senate unanimously and later advanced in the House with strong support, including a veto override vote that was overwhelmingly favorable. No committee transcript is available, but the vote pattern indicates the measure was generally viewed positively as a patient-access and pain-management policy rather than a controversial Medicaid restriction.
Contention
The main policy issue is whether Medicaid should be prohibited from favoring opioids over nonopioid pain treatments and whether nonopioid medications should receive equal or less restrictive utilization management. Potential concerns are administrative flexibility for Medicaid and managed care plans, the cost and operational impact of changing prior authorization and step therapy rules, and whether federal approval is needed to implement the changes without jeopardizing funding. The recorded votes show little overt opposition, though the House veto override included some dissent, indicating limited disagreement rather than major controversy.